Moreover, high levels of AXL are involved in crizotinib (ALK inhibitor) resistance in lung cancer patients [45] and contribute to FLT3 inhibitor resistance in acute myeloid leukemia (AML) [46]. This evidence concerns the gene ALK and lung cancer.